Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
J Occup Environ Med. 2010 Jun;52(6):618-21. doi: 10.1097/JOM.0b013e3181de8357.
To assess the effect of 12-month treatment with adalimumab on work ability, quality of life, and fatigue in patients with active rheumatoid arthritis (RA).
One hundred twenty-six patients with active RA started treatment with adalimumab. Primary outcome measurements were work ability, assessed by the first item of the Work Ability Index, quality of life, assessed by the Rheumatoid Arthritis Quality of Life (RAQoL) instrument, and fatigue, assessed by the Checklist Individual Strength and the Need for Recovery after work Scale.
All primary outcome measurements showed a significant improvement. The largest improvement for all outcome measurements was gained in the first 6 months of treatment and was sustained over the following 6 months.
Adalimumab improves patient reported outcomes in addition to improving disease activity in established RA.
评估阿达木单抗治疗 12 个月对活动性类风湿关节炎（RA）患者工作能力、生活质量和疲劳的影响。
126 例活动性 RA 患者开始接受阿达木单抗治疗。主要结局测量指标为工作能力，采用工作能力指数的第一项进行评估；生活质量，采用类风湿关节炎生活质量（RAQoL）量表进行评估；疲劳，采用个体力量检查表和工作后恢复需求量表进行评估。
所有主要结局测量指标均显示出显著改善。所有结局测量指标中最大的改善发生在治疗的前 6 个月，并在随后的 6 个月中持续。
阿达木单抗除了改善已确诊 RA 的疾病活动度外，还能改善患者报告的结局。
